RxDoctor Payments Data

Rory Duffour, MD

Family Medicine · Slidell, LANPI 1730149329

Payments from drug & device makers

$10,621in general payments, 2019–2025

Across 695 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$816
  • Pfizer$717
  • Amgen$703
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$10,56399%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,621 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,646
Medicare patients
214
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$189,414
JardianceEmpagliflozin118$106,558
TrulicityDulaglutide65$96,383
EliquisApixaban80$77,335
MounjaroTirzepatide41$40,574
FarxigaDapagliflozin Propanediol28$29,704
LinzessLinaclotide37$26,717
TradjentaLinagliptin22$23,814
JanuviaSitagliptin Phosphate20$19,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,594
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,683
KerendiaFinerenone12$11,326
SymbicortBudesonide/Formoterol Fumarate16$6,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$4,782
Rosuvastatin Calcium266$3,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,162$189,414157 claims
Lilly USA, LLCTrulicity, Mounjaro$519$136,957106 claims
Boehringer IngelheimJardiance, Tradjenta$295$130,372140 claims
PfizerEliquis$717$77,33580 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$816$47,60660 claims
AbbVieLinzess$1,069$26,71737 claims
MerckJanuvia$517$19,74620 claims
GSKTrelegy Ellipta$1,401$14,59421 claims
BayerKerendia$476$11,32612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →